PATENT COOPERATION TREATY

From the INTERNATIONAL	SEARCHING AUTHORITY	

TERESA A. LAVOIE

FISH & RICHARDSON P.C. P.O. BOX 1022 MINNEAPOLIS, MN 55440-1022	NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT AND THE WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY, OR THE DECLARATION			
	(PCT Rule 44.1)			
	Date of mailing (day/month-year) 18 JAN 2011			
Applicant's or agent's file reference	FOR FURTHER ACTION See paragraphs 1 and 4 below			
253240036WO1				
International application No. PCT/US 10/57341	International filing date (day/month/year) 19 November 2010 (19.11.2010)			
Applicant CUREMARK LLC				
The applicant is hereby notified that the international s Authority have been established and are transmitted by	search report and the written opinion of the International Searching			
Filing of amendments and statement under Article	19:			
The applicant is entitled, if he so wishes, to amend the claims of the international application (see Rule 46): When? The time limit for filing such amendments is normally two months from the date of transmittal of the				
international search report.				
Where? Directly to the International Bureau of WIPO, 34 chemin des Colombettes 1211 Geneva 20, Switzerland, Facsimile No.: +41 22 338 82 70				
For more detailed instructions, see PCT Applicant's Guide, International Phase, paragraphs 9.004 – 9.011				
The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect and the written opinion of the International Searching Authority are transmitted herewith.				
3. With regard to any protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:				
the protest together with the decision thereon has been transmitted to the International Bureau together with any request to forward the texts of both the protest and the decision thereon to the designated Offices.				
no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made				
4. Reminders				
The applicant may submit comments on an informal basis on the written opinion of the International Searching Authority to the International Bureau. The International Bureau will send a copy of such comments to all designated Offices unless an international preliminary examination report has been or is to be established. Following the expiration of 30 months from the priority date, these comments will also be made available to the public.				
Shortly after the expiration of 18 months from the priority date, the international application will be published, by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of windrawal of the international application, or of the priority claim, must reach the International Bureau before the completion of the technical preparations for international publication (Rules 90.bis.1 and 90.bis.3).				
Within 19 mouths from the priority date, but only in respect of some designated Offices, a demand for international preliminary examination must be filled if the applicant wistes to postpone the entry into the national plases until 30 months from the priority date (in some Offices even later); otherwise, the applicant must, within 20 months from the priority date, perform the prescribed acts for entry into the national phase before those designated Offices.				
In respect of other designated Offices, the time limit of 30 months (or later) will apply even if no demand is filed within 19 months.				
For details about the applicable time limits, Office by PCT Applicant's Guide, National Chapters.	Office, see www.wipo.int/pct/cn/texts/time_limits.html and the			
Name and mailing address of the ISA/	Authorized officer			
Mail Stop PCT, Attn: ISA/US	Lee W. Young			
Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450	PCT Helpdesk: 571-272-4300			
Facsimile No. 571-273-3201	Telephone No. PCT OSP. 571-272-7774			

Form PCT/ISA/220 (July 2010)

sec Form PCT/ISA/220

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

FOR FURTHER

(PCT Article 18 and Rules 43 and 44)

253240036WO1	ACTION	as well	as, where applicable, item 5 below.
International application No.	International filing date	(day/month/year)	(Earliest) Priority Date (day/month/year)
PCT/US 10/57341	19 November 2010 (19.11	.2010)	19 November 2010 (19.11.2010)
Applicant CUREMARK LLC			
This international search report has be according to Article 18. A copy is being	en prepared by this Intern g transmitted to the Interna	ational Scarching A stional Bureau.	authority and is transmitted to the applicant
This international search report consists	of a total of 1/ sl	neets.	
It is also accompanied by a	copy of each prior art doc	ument cited in this	report.
Basis of the report			
 With regard to the language, the 	international search was	carried out on the ba	sis of:
the international app	lication in the language in	which it was filed.	
a translation of the ir a translation furnishe	nternational application int ed for the purposes of inter	o national search (Ru	which is the language of les 12.3(a) and 23.1(b)).
b. This international search r authorized by or notified to	eport has been established this Authority under Rule	taking into accoust 91 (Rule 43.6bis(a	nt the rectification of an obvious mistake
c. With regard to any nucleot	ide and/or amino acid se	quence disclosed in	the international application, see Box No. I.
2. Certain claims were found	d unsearchable (see Box 1	No. 11).	*
3. Unity of invention is lack	ing (see Box No. 111).		
4 With regard to the title,			
the text is approved as sub			
the text has been established	d by this Authority to read	as follows:	
5. With regard to the abstract,			
the text is approved as sub	nitted by the applicant.		
the text has been established may, within one month from	d, according to Rule 38.2, in the date of mailing of this	by this Authority as s international searc	it appears in Box No. IV. The applicant h report, submit comments to this Authority.
6. With regard to the drawings,			
a the figure of the drawings to be	published with the abstrac	t is Figure No.	
as suggested by the a			
as selected by this Au	thority, because the application	ant failed to sugges	t a figure.
as selected by this Au	thority, because this figur	e better characterize	s the invention.
b. nonc of the figures is to be	published with the abstrac	t.	

Form PCT/ISA/210 (first sheet) (July 2009)

Applicant's or agent's file reference

INTERNATIONAL SEARCH REPORT

International application No. PCT/US 10/57341

IPC(8) - USPC - According t	SSIFICATION OF SUBJECT MATTER A61K 9/14; A61K 38/00 (2011.01) 424/94.3; 424/94.1; 424/488; 435/41 o International Patent Classification (IPC) or to both i	national classification and IPC	
	DS SEARCHED		
USPC - 424	ocumentation searched (classification system followed by 194.3; 424/94.1; 424/488; 435/41 K 9/14; A61K 38/00 (2011.01)	classification symbols)	
USPC - 424.	ion searched other than minimum documentation to the e 194.3; 424/94.1; 424/488; 435/41 K 9/14; A61K 38/00 (2011.01) (keyword delimited)	stent that such documents are included in the	fields searched
PubWEST (I	ta base consulted during the international search (name of ISPT_PCPB_EPAB_IPAB). Google is used: digestive enzymes pancreatic acid modulator of the construction of the construction of		
C. DOCU	MENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where a	ppropriate, of the relevant passages	Relevant to claim No.
X	US 6,011,001 A (Navia et al.) 04 January 2000 (04.01	.2000), col 25, ln 28-38	1-5
A	US 2004/0101562 A1 (Malo) 27 May 2004 (27.05.200	4), para [0011], [0005]	1-5
Furthe			
	categories of cited documents:		
"A" docume to be of "E" earlier a	nt defining the general state of the art which is not considered particular relevance pplication or patent but published on or after the international	"T" later document published after the intendate and not in conflict with the applicate the principle or theory underlying the improvement of particular relevance, the	ation but cited to understand nvention
"L" docume	ate It which may throw doubts on priority claim(s) or which is establish the publication date of another citation or other	considered novel or cannot be conside step when the document is taken alone	ered to involve an inventive
	reason (as specified) nt referring to an oral disclosure, use, exhibition or other	"Y" document of particular relevance; the considered to involve an inventive combined with one or more other such dbeing obvious to a person skilled in the	tep when the document is locuments, such combination
"P" docume the prior	nt published prior to the international filing date but later than rity date claimed	"&" document member of the same patent f	
	ctual completion of the international search	Date of mailing of the international search	
10 January 2	(011 (10.01,2011)	18 JAN 2011	
	ailing address of the ISA/US	Authorized officer:	
P.O. Box 1450	F, Attn: ISA/US, Commissioner for Patents D, Alexandria, Virginia 22313-1450	Lee W. Young	
	571-273-3201	PCT Helpdesk: 571-272-4300 PCT OSP: 571-272-7774	
Form PCT/IS/	1/210 (second sheet) (July 2009)		

PATENT COOPERATION TREATY

To. TERESA A. LAVOIE FISH & RICHARDSON P.C. P.O. BOX 1022 MINNEAPOLIS, MN 55440-1022	PCT WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1)		
	Date of mailing (day/month/year) 18 JAN 2011		
Applicant's or agent's file reference	FOR FURTHER ACTION		
253240036WO1 .	See paragraph 2 below		
1	ling date (day/month/year) Priority date (day/month/year)		
	er 2010 (19.11.2010) 19 November 2010 (19.11.2010)		
International Patent Classification (IPC) or both national IPC(8) - A61K 9/14; A61K 38/00 (2011.01) USPC - 424/94.3; 424/94.1; 424/488; 435/41	classification and IPC		
Applicant CUREMARK LLC			
This opinion contains indications relating to the following to the fo	wing items:		
Box No. I Basis of the opinion			
Box No. II Priority			
Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability			
Box No. IV Lack of unity of invention			
Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability citations and explanations supporting such statement			
Box No. VI Certain documents cited			
Box No. VII Certain defects in the internation	onal application		
Box No. VIII Certain observations on the int	ernational application		
2. FURTHER ACTION			
If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("PIEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66. Ibia(b) that written opinions of this International Searching Authority will not be so considered.			
If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/2/20 or before the expiration of 22 months from the priority date, whichever expires later.			
For further options, see Form PCT/ISA/220.			
For further details, see notes to Form PCT/ISA/220.			
1			
Name and mailing address of the ISA/US Date of comple	etion of this opinion Authorized officer:		
Mail Stop PCT, Attn: ISA/US Commissioner for Palents	Lee W Young		
P.O. Box 1450, Alexandria, Virginia 22313-1450	2011 (10.01.2011) PCT Helpdesk: 571-272-4300		
Facsimile No. 571-273-3201 Form PCT/ISA/237 (cover sheet) (July 2009)	PCT OSP: 571-272-7774		

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/US 10/57341

_	
Зох	r No. I Basis of this opinion
I.	With regard to the language, this opinion has been established on the basis of: X the international application in the language in which it was filed. a translation of the international application into translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
2.	This opinion has been established taking into account the rectification of an obvious mistake authorized by or notified to this Authority under Rule 91 (Rule 43bts.1(a))
3.	With regard to any nucleotide and/or amino acid sequence disclosed in the international application, this opinion has been established on the basis of a sequence listing filed or furnished:
	a. (means) on paper in electronic form
	b. (time)
	in the international application as filed
	together with the international application in electronic form subsequently to this Authority for the purposes of search
	subsequently to this Authorny for the purposes of search
4.	In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
5.	Additional comments:
	•

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.
PCT/US 10/57341

Box No. V Reasoned statement und citations and explanatio		ons supporti	bis.1(a)(i) with regard to novelty, inventiving such statement	e step or industrial applicability;
1. Stateme	nt			
Novelty (N)	lty (N)	Claims	2	YES
		Claims	1, 3-5	NO NO
Inventive step (IS)	Claims	None	YES	
		Claims	1-5	NO NO
Indus	trial applicability (IA)	Claims	1-5	YES
		Claims	None	NO

2. Citations and explanations:

Claims 1 and 3-5 lack novelty under PCT Article 33(2) as being anticipated by US 6,011,001 A to Navia et al. (hereinafter Navia).

Regarding claim 1. Navia discloses a pharmaceutical composition comprising one or more digestive enzymes, wherein the one or more digestive enzymes are optionally coated, and one or more gastrointestinal modulators of acid, or pharmaceutically acceptable salts thereof (cot 25. in 28-38).

Regarding claim 3, Navia discloses the pharmaceutical composition of claim 1, wherein the one or more digestive enzymes comprise pancreatic enzymes (col 25, In 28-38).

Regarding claim 4, Navia discloses the pharmaceutical composition of claim 1, wherein the one or more digestive enzymes comprises at least one amylase, lipase, and protease (col 25, ln 28-38).

Regarding claim 5, Navia discloses the pharmaceutical composition of claim 1, wherein the pharmaceutical composition is coated (col 25, in 28-38).

Claim 2 lacks an inventive step under PCT Article 33(3) as being obvious over Navia.

Regarding claim 2, Navia discloses the pharmaceutical composition of claim 1, but does not specifically disclose wherein the coating is a lipid coating; however, it would have been obvious to one of skill in the art to use a lipid coating to protect the enzyme from stomach acid inactivation until the enzyme reaches the duodenum and small intestine.

Claims 1-5 have industrial applicability as defined by PCT Article 33(4) because the subject matter can be made or used in industry.